Katalog CVE
CVSS 8.8 · High
KEV · sudah dieksploitasi
EPSS 0,59%
Kerentanan Improper Authorization pada google android. Skor CVSS 3.1 8.8 (High) menurut CISA ADP. Masuk katalog KEV CISA pada 16 September 2026, artinya sudah terbukti dieksploitasi.
Deskripsi (NVD)
In Cellular Modem, there is a possible permission bypass due to a logic error in the code. This could lead to remote (proximal/adjacent) escalation of privilege with no additional execution privileges needed. User interaction is not needed for exploitation.
Advisory KUTIM-CSIRT
Rincian
- Terbit di NVD
- 15 September 2026
- Terakhir diubah
- 7 Oktober 2026
- Status NVD
- Analyzed
- CVSS 3.1
- 8.8 (High), sumber CISA ADP
CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H
· uraikan di kalkulator
- Jenis kelemahan (CWE)
-
CWE-285: Improper Authorization
CWE-693: Protection Mechanism Failure
- EPSS (30 hari)
- 0,59% peluang dieksploitasi; lebih tinggi dari 46,8% CVE lain
Known Exploited Vulnerabilities (CISA)
- Nama
- Google Pixel Improper Authorization Vulnerability
- Masuk KEV
- 16 September 2026
- Tenggat CISA
- 19 September 2026 (untuk instansi federal AS)
- Ransomware
- Belum tercatat
- Tindakan wajib
- Apply mitigations in accordance with vendor instructions, ensuring compliance with CISA’s BOD 26-04 Prioritizing Security Updates Based on Risk (see URL in Notes) guidance and CISA’s “Forensics Triage Requirements” (see URL in Notes). Follow applicable BOD 26-04 guidance for cloud services or discontinue use of the product if mitigations are unavailable. Stakeholders are responsible for evaluating each asset's internet exposure and ensuring adherence to BOD 26-04 patching guidelines.
Produk dan versi terdampak
| Vendor | Produk | Versi terdampak |
| google |
android |
Semua versi |
> Data dari konfigurasi CPE di NVD.
Referensi dan perbaikan
Sumber:
NVD ·
CVE.org
·
KEV CISA
·
EPSS.
Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 8 Okt 2026, 06:25 WITA.
Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat
kanal pelaporan.